← Back to All US Stocks

Cybin Inc.. (HELP) Fundamental Analysis & AI Grade 2026

HELP Nasdaq Pharmaceutical Preparations A6 CIK: 0001833141
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Cybin Inc.. (HELP) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

HELP Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

HELP vs Healthcare Sector: How Cybin Inc.. Compares

How Cybin Inc.. compares to Healthcare sector averages

Net Margin
HELP 0.0%
vs
Sector Avg 12.0%
HELP Sector
ROE
HELP 0.0%
vs
Sector Avg 15.0%
HELP Sector
Current Ratio
HELP 0.0x
vs
Sector Avg 2.0x
HELP Sector
Debt/Equity
HELP 0.0x
vs
Sector Avg 0.6x
HELP Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Cybin Inc.. Stock Overvalued? HELP Valuation Analysis 2026

Based on fundamental analysis, Cybin Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Cybin Inc.. Balance Sheet: HELP Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

HELP Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

HELP SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Cybin Inc.. (CIK: 0001833141)

📋 Recent SEC Filings

Date Form Document Action
Dec 3, 2024 SC 13G j1126240sc13g.htm View →
Aug 27, 2024 SC 13G cybn13g.htm View →
Mar 25, 2024 SC 13G tm249699d1_sc13g.htm View →
Mar 22, 2024 SC 13G deeptrack-cybn031424.htm View →
Nov 7, 2023 SC 13G sc13g.htm View →

Frequently Asked Questions about HELP

What is the AI rating for HELP?

Cybin Inc.. (HELP) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are HELP's key strengths?

Claude: Analysis in progress.

What are the risks of investing in HELP?

Claude: Analysis in progress.

What is HELP's revenue and growth?

Cybin Inc.. reported revenue of N/A.

Does HELP pay dividends?

Cybin Inc.. does not currently pay dividends.

Where can I find HELP SEC filings?

Official SEC filings for Cybin Inc.. (CIK: 0001833141) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is HELP's EPS?

Cybin Inc.. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is HELP's fundamental grade?

Based on our AI fundamental analysis in May 2026, Cybin Inc.. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is HELP stock overvalued or undervalued?

Valuation metrics for HELP: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is HELP's AI grade for 2026?

Our dual AI analysis gives Cybin Inc.. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is HELP's free cash flow?

Cybin Inc..'s operating cash flow is N/A, with capital expenditures of N/A.

How does HELP compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI